BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 2.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 842,771 shares of the medical equipment provider’s stock after purchasing an additional 18,473 shares during the period. Geode Capital Management LLC owned about 1.82% of BioLife Solutions worth $21,107,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC grew its stake in BioLife Solutions by 20.1% during the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock worth $1,613,000 after buying an additional 10,803 shares during the last quarter. State Street Corp boosted its holdings in shares of BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after acquiring an additional 95,788 shares during the period. Stifel Financial Corp grew its position in shares of BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after acquiring an additional 670 shares during the last quarter. Mark Sheptoff Financial Planning LLC acquired a new position in shares of BioLife Solutions in the 3rd quarter valued at $28,000. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of BioLife Solutions by 81.3% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after acquiring an additional 262,504 shares during the period. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $26.59 on Friday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -25.08 and a beta of 1.91. The business’s 50 day moving average is $25.28 and its two-hundred day moving average is $23.91. BioLife Solutions, Inc. has a 12-month low of $14.50 and a 12-month high of $28.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

Insider Activity at BioLife Solutions

In other news, EVP Aby J. Mathew sold 25,000 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $21.17, for a total value of $529,250.00. Following the completion of the transaction, the executive vice president now owns 302,046 shares in the company, valued at $6,394,313.82. This trade represents a 7.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 64,259 shares of company stock worth $1,424,708 over the last three months. 2.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BLFS. TD Cowen increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Benchmark reiterated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright dropped their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Craig Hallum increased their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, KeyCorp boosted their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.00.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.